• ORR by irRC. • PFS by RECIST Version 1.1 . • PFS by irRC. • OS. • DOR by RECIST Version 1.1 and irRC. • DCR (confirmed CR, PR, or stable disease [SD] lasting for at least 2 months) by RECIST Version 1.1 and irRC . • QoL by PROs. Exploratory Endpoints: • Tumor molecular profiles and correlations with subject outcomes. • Therapy- induced changes in immune responses and correlations with subject outcomes. • Molecula r changes in ctDNA and ctRNA and correlations with subject outcomes. Phase 2 Primary Endpoint: • ORR by RECIST Version 1.1. Secondary Endpoints: • ORR by irRC. • PFS by RECIST Version 1.1 . • PFS by irRC. • OS. • DOR by RECIST Version 1.1 and irRC. • DCR (confirmed CR, PR, or SD lasting for at least 2 months) by RECIST Version 1.1 and irRC. • QoL by PROs. NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 1 Confidential and Proprietary 10 • Incidence of treatment- emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03. Exploratory Endpoints: • Tumor molecular profiles and correlations with subject outcomes. • Therapy- induced changes in immune responses and correlations with subject outcomes. • Molecular changes in ctDNA and ctRNA and correlations with subject outcomes. Enrollment (planned): In the phase 1b portion of the study, 6 to 24 subjects will be enrolled. The initial 3 subjects will be enrolled in a staggered fashion, with a 21- day interval between each subject. In the phase 2 portion of the study, 19 subjects will be enrolled in the first stage of Simon’s two- stage optimal design. If the study proceeds to the second stage of Simon’s two -stage optimal design, an additional 36 subjects will be enrolled in the second stage, for a total of 55 subjects in the phase 2 portion of the study. The maximum total enrollment for the study is 79 subjects. Eligibility Criteria: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.